2015 GI Cancers Symposium - Saturday
Read More
Josep Tabernero, MD, PhD, presenting "Abstract 512: RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp)."
San Francisco, CA - 2015 Gastrointestinal Cancers Symposium : Josep Tabernero, MD, PhD, presenting "Abstract 512: RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp)." during Oral Abstract Session: Cancers of the Colon, Rectum and Anus at the Gastrointestinal Cancers Symposium 2015 here today, Saturday January 17, 2015. The Symposium is supported by ASCO, the American Society of Clinical Oncology, ASTRO, The American Society of Radiation Oncology, SSO, Society of Surgical Oncology and the AGA Institute. Over 3,000 physicians, researchers and allied healthcare professionals are attending the meeting which is being held at the Moscone West center in San Francisco and features the latest Gastrointestinal Cancers research in the areas of basic and clinical science. Date: Saturday January 17, 2015. Photo by © ASCO/Todd Buchanan 2015 Technical Questions: todd@medmeetingimages.com; Phone: 612-226-5154. GI15_DailyNews
